Author Relationships with Industry and Other Entities
| Committee Member | Employment | Consultant | Speakers Bureau | Ownership/Partnership/Principal | Personal Research | Institutional, Organizational, or Other Financial Benefit | Expert Witness |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Ray Hershberger | Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH | Array Biopharma | None | None | None | None | None |
| Michael M. Givertz | Brigham and Women’s Hospital, Harvard Medical School, Boston, MA | None | None | None | None | None | None |
| Carolyn Ho | Brigham and Women’s Hospital, Harvard Medical School, Boston, MA | Myokardia | None | None | None | Myokardia | None |
| Daniel P. Judge | Johns Hopkins University School of Medicine | Array Biopharma, Eidos Therapeutics, Glaxo Smith Kline, Invitae, Myokardia, Pfizer | None | None | Pfizer | None | None |
| Paul F. Kantor | University of Alberta, Stollery Children’s Hospital, Edmonton, AB, Canada | None | None | None | None | None | None |
| Kim L McBride | Nationwide Children’s Hospital and College of Medicine, Ohio State University, Columbus, OH | None | None | None | None | None | None |
| Ana Morales | Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH | None | None | None | None | None | None |
| Matt Taylor | University of Colorado Denver | Array Biopharma, Guidepoint Global, Wellpoint | GeneDx | None | None | None | None |
| Matteo Vatta | Indiana University, Indianapolis, IN; Invitae Corporation, San Francisco, CA | None | None | Invitae Corporation, San Francisco, CA | None | Invitae Corporation, San Francisco,CA | None |
| Stephanie M. Ware | Indiana University School of Medicine, Indianapolis, IN | None | None | None | None | None | None |
This table represents the relationships of committee members with industry and other entities that were determined to be possibly relevant to this document. These relationships were reviewed and updated in conjunction with meetings and/or conference calls of the writing committee during the document development process. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.